Plasma cholesterol which is one of risk factors for the development of coronary heart disease is derived both from dietry fat and de novo synthesis by the liver1}. There are two main therapeutical approaches to lower plasma cholesterol. The first is to stimulate removal of cholesterol by using an ion exchanger like cholestyramine, which absorbs bile acids synthesized from cholesterol and results in excretion of it from the body as an ion complex. The second is a newer approach to use inhibitory effect on cholesterol biosynthesis of the liver because it is a major site of lipoprotein synthesis. In this pathway, 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a rate-limiting enzyme to convert HMG-CoA to mevalonate. As a function of this enzyme is inhibited, incorporation of cholesterol by the hepatocyte is increased by upregulation of low density lipoprotein-receptor (LDL-R). Compactin was discovered first as HMG-CoA reductase inhibitor from culture broth of fungi2). There were also effective agents including pravastatin, lovastatin, simbastatin and fluvastatin, which were developed by modification of compactin to produce moreeffective derivatives2). In the course of our screen for LDL-Rupregulators, we found that Fig. 1 . It indicated that concanamycin and bafilomycin Cl at 0.4^g/ml showed potent LDL-Rupregulation activities (3.7 and 6.0 vs. control in upregulation index of LDL-RmRNA; Ulm, respectively) while fluvastatin (positive compound, synthesized by W. E. Harte in BristolMyers Squibb Company), 2.7 vs. control in Ulm at 0.4/zg/ml. The activity of PC-766B (3.1 vs. control in Ulm) is close to that of fluvastatin. During purification of PC-766B, another active fraction was isolated as a minor component. This fraction showed 7.0 in UI at 2/ig/ml as LDL-R mRNA upregulation activity when fluvastatin showed 3.6 in UI at 0.4/ig/ml.
As to antibacterial activities of the 16-or 18-memberedmacrolides used here, although we did not investigate their bactericidal activities in detail, the purified material in our laboratory, PC-766B, was active against Saccharomyces cerevisiae at concentration below 0.0625//g/ml and Candida albicans at 0.78/ig/ml as minimum inhibitory concentration (MIC) while not active against Staphylococcus aureus or Bacillus subtHis (up to 0.5jUg/ml).
The literature values of MIC were obtained from several laboratories; PC-766B and bafilomycins showed l~13 /xg/ml and 9^40^g/ml
as MIC values against Gram-positive bacteria, fungi and yeast3A) while concanamycins exhibited l~3/ig/ml as MIC values against fungi5). It seems that there is not clear relationship between antibacterial and LDL-Rupregulation activities of these macrolide antibiotics.
To examine whether elevated concentration of LDL-R mRNAby the compounds is due to stimulation of transcription of LDL-R gene or decrease of LDL-R mRNAdegradation, the effects of these compounds on the expression of LDL-R HepG2(5 x 106, a gift of Bristol-Myeres Squibb Institute at Wallirigford, CT) were cultured in RPMI 1640 supplemented with 10% fetal bovine serum for 3 days using a collagen-coated plate (Corning, NY). The plates were washed and 3 ml of RPMI1640 (Nissui Pharmaceutical Co. Ltd., Tokyo) supplemented with 2% lipoprotein deficient human serum (LPDS, Sigma Chemical Co., MO)was added. The cells were incubated with or without test samples for 20 hours at 37°C in a humidified atmosphere of 5% CO2incubator. Whole RNA(180jug) was extracted according to the method of Chomczynsky and Sacchi8). Northern blot analysis was carried out by the method of Sambrook et al.9\ Cellular RNA (for LDL-RmRNA: about one sixth of whole RNApreparation, /?-actin mRNA: 1/100 of that) was separated by formaldehyde (2.2 M)-denatured 1 % agarose gel, blotted onto a nylon membrane (Nytran-N, Schleicher and Schuell, Dassel, Fed. Rep. of Germany) and hybridized with a 32P-labeled CDNAprobes (1 -5 x 106cpm/ml solution for hybridization); for LDL-R: human LDL-R CDNA(the Xbal-EcoRl digestion of PUCLDLR4), was a gift of Dr. T. Yamamoto(Tohoku University), and exonl8 of LDL-R gene (0.7 kb) prepared by BamH l-Sma l digestion of pUC19 LDL, for^-actin: 2. 1 kb fragment obtained from BamRldigestion of LK221. 32P-Labelling for the probes was carried out by a random primed DNAlabeling kit purchased from Boehringer Mannheim. Following hybridization, the filters was washed, and subjected to autoradiography. Autoradiogram (Panel A) was monitored to determine the relative amounts of mRNA by densitometric scanning after exposure of the filter to Kodak XAR-5;each lane is as follows; control (lane 1 and 2), fluvastatin (lane 3 and 4; l /iM=0.4/ig/ml), PC-766B (lane 5 and 6; 0.4/xg/ml, lane 7 and 8; 2/ig/ml), concanamycin (lane 9 and 10; 0.4/xg/ml, lane ll and 12; 2/ig/ml), bafilomycin Al (lane 13 and 14; 0.4/ig/ml, lane 15 and 16; 2jug/ml), bafilomycin Cl (lane 17 and 18; 0.4/ig/ml, lane 19 and 20; 2/ig/ml). The peak areas for LDL-RmRNAor the peak height for /?-actin mRNA used as internal control were measured. A ratio of LDL-RmRNA to /?-actin's was calculated, and upregulation index (UI) was determined by dividing of the ratio of test sample by that of control.
The data represent the means of the duplicate determinations (Panel B 
